Abstract Objective To investigate the incidence rates of Clostridium difficile colonization and Clostridium difficile infection (CDI) in children with inflammatory bowel disease (IBD) and the susceptibility factors for CDI in children with IBD. Methods A total of 62 children diagnosed with IBD were enrolled as the IBD group. Forty-two children who attended the hospital due to persistent or chronic diarrhea and were excluded from IBD were enrolled as the non-IBD group. The incidence rate of CDI was compared between the two groups. According to the presence or absence of CDI, the IBD group was subdivided into two groups:IBD+CDI (n=12) and non-CDI IBD (n=50), and the clinical data were collected from the two groups to analyze the susceptibility factors for CDI. Results The IBD group had a significantly higher incidence rate of CDI[19% (12/62) vs 2% (1/42); P < 0.05] than the non-IBD group (P < 0.05). Compared with the non-CDI IBD group, the IBD+CDI group had a significantly longer disease course (P < 0.05), and a significantly higher proportion of children with fever, diarrhea, or abdominal pain (P < 0.05). The IBD+CDI group had significantly higher activity indices of pediatric Crohn's disease, C-reactive protein levels and erythrocyte sedimentation rate than the non-CDI IBD group (P < 0.05). The univariate analysis showed that compared with the non-CDI IBD group, the IBD+CDI group had a significantly higher proportion of children with moderate-to-severe disease, use of glucocorticoids, or treatment with broad-spectrum antibiotics for more than 14 days before diagnosis (P < 0.05). Conclusions The children with IBD have a higher incidence of CDI than those without IBD. Severe disease conditions and use of broad-spectrum antibiotics or glucocorticoids may be associated with an increased incidence of CDI in children with IBD.
ZHANG Wen-Ting,ZHAO Hong-Mei,LUO Yan-Hong et al. Clostridium difficile infection and its susceptibility factors in children with inflammatory bowel disease[J]. CJCP, 2021, 23(7): 718-723.
ZHANG Wen-Ting,ZHAO Hong-Mei,LUO Yan-Hong et al. Clostridium difficile infection and its susceptibility factors in children with inflammatory bowel disease[J]. CJCP, 2021, 23(7): 718-723.
Ng SC. Emerging leadership lecture:inflammatory bowel disease in Asia:emergence of a "Western" disease[J]. J Gastroenterol Hepatol, 2015, 30(3):440-445. DOI:10.1111/jgh.12859. PMID:25469874.
[2]
Chou JW, Lai HC, Chang CH, et al. Epidemiology and clinical outcomes of inflammatory bowel disease:a hospital-based study in Central Taiwan[J]. Gastroenterol Res Pract, 2019, 2019:4175923. DOI:10.1155/2019/4175923. PMID:31312216. PMCID:PMC6595318.
[3]
Su HJ, Chiu YT, Chiu CT, et al. Inflammatory bowel disease and its treatment in 2018:global and Taiwanese status updates[J]. J Formos Med Assoc, 2019, 118(7):1083-1092. DOI:10.1016/j.jfma.2018.07.005. PMID:30054112.
[4]
D'Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with Clostridium difficile infection[J]. World J Gastroenterol, 2017, 23(27):4986-5003. DOI:10.3748/wjg.v23.i27.4986. PMID:28785153. PMCID:PMC5526769.
Gómez S, Chaves F, Orellana MA. Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection[J]. Anaerobe, 2017, 48:147-151. DOI:10.1016/j.anaerobe.2017.08.012. PMID:28830842.
[7]
Kim DH, Cho JM, Yang HR. Clostridium difficile infection at diagnosis and during the disease course of pediatric inflammatory bowel disease[J]. Pediatr Gastroenterol Hepatol Nutr, 2018, 21(1):43-50. DOI:10.5223/pghn.2018.21.1.43. PMID:29383304. PMCID:PMC5788950.
[8]
Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States[J]. N Engl J Med, 2015, 372(9):825-834. DOI:10.1056/NEJMoa1408913. PMID:25714160.
[9]
Hourigan SK, Oliva-Hemker M, Hutfless S. The prevalence of Clostridium difficile infection in pediatric and adult patients with inflammatory bowel disease[J]. Dig Dis Sci, 2014, 59(9):2222-2227. DOI:10.1007/s10620-014-3169-4. PMID:24788321.
[10]
Schutze GE, Willoughby RE, Committee on Infectious Diseases, et al. Clostridium difficile infection in infants and children[J]. Pediatrics, 2013, 131(1):196-200. DOI:10.1542/peds.2012-2992. PMID:23277317.
[11]
Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease:understanding the evolving relationship[J]. World J Gastroenterol, 2010, 16(39):4892-4904. DOI:10.3748/wjg.v16.i39.4892. PMID:20954275. PMCID:PMC2957597.
Turner D, Griffiths AM, Walters TD, et al. Appraisal of the Pediatric Crohn's Disease Activity Index on four prospectively collected datasets:recommended cutoff values and clinimetric properties[J]. Am J Gastroenterol, 2010, 105(9):2085-2092. DOI:10.1038/ajg.2010.143. PMID:20372111.
[14]
Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a Pediatric Ulcerative Colitis Activity Index:a prospective multicenter study[J]. Gastroenterology, 2007, 133(2):423-432. DOI:10.1053/j.gastro.2007.05.029. PMID:17681163.
[15]
Sokol H, Jegou S, McQuitty C, et al. Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection[J]. Gut Microbes, 2018, 9(1):55-60. DOI:10.1080/19490976.2017.1361092. PMID:28786749. PMCID:PMC5914915.
[16]
Wultańska D, Banaszkiewicz A, Radzikowski A, et al. Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease[J]. Eur J Clin Microbiol Infect Dis, 2010, 29(10):1265-1270. DOI:10.1007/s10096-010-0997-9. PMID:20577773. PMCID:PMC2937146.
[17]
Markowitz JE, Brown KA, Mamula P, et al. Failure of single-toxin assays to detect Clostridium difficile infection in pediatric inflammatory bowel disease[J]. Am J Gastroenterol, 2001, 96(9):2688-2690. DOI:10.1111/j.1572-0241.2001.04125.x. PMID:11569696.
[18]
Pascarella F, Martinelli M, Miele E, et al. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease[J]. J Pediatr, 2009, 154(6):854-858. DOI:10.1016/j.jpeds.2008.12.039. PMID:19230908.
[19]
Sokol H, Lalande V, Landman C, et al. Clostridium difficile infection in acute flares of inflammatory bowel disease:a prospective study[J]. Dig Liver Dis, 2017, 49(6):643-646. DOI:10.1016/j.dld.2017.01.162. PMID:28215602.
[20]
Erb S, Frei R, Strandén AM, et al. Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients[J]. Clin Microbiol Infect, 2015, 21(11):998.e9-998.e15. DOI:10.1016/j.cmi.2015.07.016. PMID:26232535.
[21]
Balram B, Battat R, Al-Khoury A, et al. Risk factors associated with Clostridium difficile infection in inflammatory bowel disease:a systematic review and meta-analysis[J]. J Crohns Colitis, 2019, 13(1):27-38. DOI:10.1093/ecco-jcc/jjy143. PMID:30247650.
[22]
Hourigan SK, Chirumamilla SR, Ross T, et al. Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2013, 19(13):2744-2752. DOI:10.1097/01.MIB.0000435434.53871.36. PMID:24145927.
[23]
Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease[J]. Cell Host Microbe, 2014, 15(3):382-392. DOI:10.1016/j.chom.2014.02.005. PMID:24629344. PMCID:PMC4059512.
[24]
Hung YP, Lee JC, Tsai BY, et al. Risk factors of Clostridium difficile-associated diarrhea in hospitalized adults:vary by hospitalized duration[J]. J Microbiol Immunol Infect, 2021, 54(2):276-283. DOI:10.1016/j.jmii.2019.07.004. PMID:31522990.
[25]
Kariv R, Navaneethan U, Venkatesh PG, et al. Impact of Clostridium difficile infection in patients with ulcerative colitis[J]. J Crohns Colitis, 2011, 5(1):34-40. DOI:10.1016/j.crohns. 2010.09.007. PMID:21272802.
